|
시장보고서
상품코드
2102095
파상풍 톡소이드 백신 시장 규모, 점유율, 성장 분석 : 제품 유형별(백신, 파상풍 함유 혼합 백신), 연령층별, 용도별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Tetanus Toxoid Vaccine Market Size, Share, and Growth Analysis, By Product Type Vaccine, Combination Tetanus-Containing Vaccines, By Age Group, By Application, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 파상풍 톡소이드 백신 시장 규모는 2024년에 58억 1,000만 달러로 평가되었으며, 2025년 61억 3,000만 달러에서 2033년까지 95억 5,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 5.67%로 성장할 것으로 전망됩니다.
세계 파상풍 톡소이드 백신 시장은 취약 계층의 근육 경직 및 사망을 예방하는 데 매우 중요한, 임산부 및 신생아의 파상풍 근절을 목표로 하는 노력에 힘입어 눈부신 성장을 이루고 있습니다. 특히 저소득 지역에서의 예방접종 활동 강화로 인해 접종률이 획기적으로 향상되었으며, WHO 프로그램의 유효성이 입증되고 있습니다. 수요의 급증에 따라 각 제조사들은 생산능력 확충과 공급망 효율화를 추진하고 있으며, 그 결과 연간 수백만 회분의 백신이 공급되고 있습니다. 또한, 이 백신이 모자 보건 패키지에 포함됨에 따라 예방접종과 산전 검진이 연계되어 수요가 더욱 촉진되고 있습니다. 이러한 상호 연계는 파상풍 발생률을 낮춤으로써 치료비를 절감할 뿐만 아니라, 각국 정부가 예방 조치에 더 많은 자원을 할당하도록 촉진하며, 시장에서 파트너십, 기술 이전, 혁신적인 제제 개발을 위한 풍부한 기회를 창출하고 있습니다.
세계 파상풍 톡소이드 백신 시장의 성장요인
국가 예방접종 프로그램에 파상풍 토코이드의 채택이 확대됨에 따라, 신흥 시장과 성숙 시장 모두에서 수요가 크게 촉진되고 있습니다. 이러한 관심 증가는 백신 조달 및 배포에 투입되는 정부의 투자와 더불어, 임산부와 어린이에게 백신의 중요성을 강조하는 노력에 힘입어 가속화되고 있습니다. 공중보건 캠페인이 정기 예방접종을 권장함에 따라 시장 접근성이 확대되고, 이를 통해 안정적인 생산 수준이 유지될 뿐만 아니라 제조사들이 공급망을 강화하도록 촉진되고 있습니다. 결국, 이러한 예방접종 활동의 범위 확대는 전 세계 파상풍 독소이드 백신 시장의 지속적인 성장을 촉진하는 데 매우 중요한 역할을 하고 있습니다.
세계 파상풍 톡소이드 백신 시장의 제약요인
세계 파상풍 톡소이드 백신 시장은 온도에 민감한 콜드체인 물류에 대한 의존도가 높기 때문에 특히 외딴 지역이나 자원이 제한된 지역에서 취약성이 발생하여 큰 제약에 직면해 있습니다. 부족한 냉장 시설, 불안정한 전력 공급, 그리고 물류상의 과제는 모두 백신의 효능을 저해할 우려가 있으며, 그 결과 제품 폐기나 의료 종사자들의 신뢰 저하를 초래할 가능성이 있습니다. 이러한 과제는 운영 비용을 상승시키고, 유통업체가 고위험 지역으로의 진출을 주저하게 만드는 요인이 되어 백신 접종률 확대를 저해하고 있습니다. 공급망 내의 이러한 취약성은 시장 성장의 큰 장애물이 되고 있으며, 전 세계 파상풍 톡소이드 백신 안정적 공급을 제한하고 있습니다.
세계 파상풍 톡소이드 백신 시장 동향
세계 파상풍 톡소이드 백신 시장은 신흥 시장, 특히 아프리카, 동남아시아, 라틴아메리카에서의 예방접종 프로그램 확대에 힘입어 눈부신 성장을 이루고 있습니다. 각국 정부는 종합적인 보건 정책에 파상풍 예방을 포함시킴으로써 모자 보건을 점점 더 우선순위로 삼고 있습니다. 국제 NGO 및 다자간 기구와의 협력을 통해 재정적·기술적 지원이 촉진되고 있으며, 이를 통해 비용 측면의 장벽이 낮아지고 있습니다. 보건 인프라 확충과 아웃리치 활동 강화를 통해 외딴 지역 주민들의 접근성이 개선되고, 지속가능한 조달 주기가 실현되고 있습니다. 이러한 변화에 발맞춰 각 제약사는 생산 규모를 확대하고 전략적인 민관 파트너십을 구축함으로써, 공공 부문 전반의 수요 증가에 확실하게 대응할 수 있게 되었습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 파상풍 톡소이드 백신 시장 규모 : 제품 유형별
세계의 파상풍 톡소이드 백신 시장 규모 : 연령층별
세계의 파상풍 톡소이드 백신 시장 규모 : 용도별
세계의 파상풍 톡소이드 백신 시장 규모 : 최종사용자별
세계의 파상풍 톡소이드 백신 시장 규모 : 유통 채널별
세계의 파상풍 톡소이드 백신 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.05Global Tetanus Toxoid Vaccine Market size was valued at USD 5.81 Billion in 2024 and is poised to grow from USD 6.13 Billion in 2025 to USD 9.55 Billion by 2033, growing at a CAGR of 5.67% during the forecast period (2026-2033).
The global Tetanus Toxoid vaccine market is experiencing significant growth driven by initiatives aimed at eradicating maternal and neonatal tetanus, crucial for preventing muscle rigidity and fatalities among vulnerable populations. Enhanced immunization efforts, particularly in low-income regions, have dramatically increased coverage rates, showcasing the effectiveness of WHO programs. The demand surge has prompted manufacturers to enhance production capabilities and improve supply chain efficiencies, resulting in millions of doses being distributed annually. Inclusion of the vaccine in maternal-child health packages further boosts demand by linking immunization with antenatal care. This interconnectedness not only lowers treatment costs by reducing tetanus incidences but also encourages governments to allocate more resources towards preventive measures, creating ample opportunities for partnerships, technology transfer, and innovative formulations in the market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tetanus Toxoid Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Tetanus Toxoid Vaccine Market Segments Analysis
Global tetanus toxoid vaccine market is segmented by product type, age group, application, end user, distribution channel and region. Based on product type, the market is segmented into Monovalent Tetanus Toxoid (TT) Vaccine and Combination Tetanus-Containing Vaccines (DT, Td, DTaP, Tdap, Pentavalent, Hexavalent, Others). Based on age group, the market is segmented into Pediatric, Adolescents, Adults and Geriatric. Based on application, the market is segmented into Routine Immunization, Maternal Immunization, Post-Exposure Prophylaxis (Wound Management), Travel Immunization and Occupational Immunization. Based on end user, the market is segmented into Hospitals, Clinics, Vaccination & Immunization Centers, Community Healthcare Centers and Occupational Health Centers. Based on distribution channel, the market is segmented into Public Immunization Programs, Private Healthcare Providers and Government Procurement & International Agencies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Tetanus Toxoid Vaccine Market
The growing inclusion of tetanus toxoid in national immunization programs acts as a significant catalyst for demand in both emerging and established markets. This heightened interest is bolstered by government investments dedicated to procuring and distributing the vaccine, alongside initiatives that emphasize its importance for pregnant women and children. As public health campaigns advocate for routine vaccinations, they facilitate wider market access, thereby promoting consistent production levels and encouraging manufacturers to strengthen their supply chains. Ultimately, the expanding scope of these immunization efforts plays a crucial role in fostering the ongoing growth of the global tetanus toxoid vaccine market.
Restraints in the Global Tetanus Toxoid Vaccine Market
The Global Tetanus Toxoid Vaccine market faces significant constraints due to its dependence on temperature-sensitive cold chain logistics, which leads to vulnerabilities, particularly in remote or resource-limited areas. Inadequate refrigeration facilities, unreliable power supplies, and logistical challenges can all jeopardize vaccine efficacy, resulting in product wastage and diminished trust among healthcare providers. Such challenges escalate operational costs and discourage distributors from reaching high-risk regions, hindering the expansion of vaccine coverage. This fragility within the supply chain serves as a major obstacle to market growth, restricting the consistent availability of the tetanus toxoid vaccine worldwide.
Market Trends of the Global Tetanus Toxoid Vaccine Market
The Global Tetanus Toxoid Vaccine market is witnessing significant growth driven by an expansion of immunization programs in emerging markets, particularly in Africa, Southeast Asia, and Latin America. Governments are increasingly prioritizing maternal and child health by integrating tetanus protection into comprehensive health initiatives. Collaborations with international NGOs and multilateral organizations facilitate financial and technical assistance, thereby lowering cost barriers. Enhanced health infrastructure and outreach efforts are enabling better access to remote populations, resulting in sustained procurement cycles. This evolution prompts manufacturers to scale production and develop strategic public-private partnerships, ensuring a robust response to growing demand across the public sector.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Tetanus Toxoid Vaccine Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Monovalent Tetanus Toxoid (TT) Vaccine
- Combination Tetanus-Containing Vaccines (DT, Td, DTaP, Tdap, Pentavalent, Hexavalent, Others)
Global Tetanus Toxoid Vaccine Market Size by Age Group & CAGR (2026-2033)
- Market Overview
- Pediatric
- Adolescents
- Adults
- Geriatric
Global Tetanus Toxoid Vaccine Market Size by Application & CAGR (2026-2033)
- Market Overview
- Routine Immunization
- Maternal Immunization
- Post-Exposure Prophylaxis (Wound Management)
- Travel Immunization
- Occupational Immunization
Global Tetanus Toxoid Vaccine Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Clinics
- Vaccination & Immunization Centers
- Community Healthcare Centers
- Occupational Health Centers
Global Tetanus Toxoid Vaccine Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Public Immunization Programs
- Private Healthcare Providers
- Government Procurement & International Agencies
Global Tetanus Toxoid Vaccine Market Size & CAGR (2026-2033)
- North America (Product Type, Age Group, Application, End User, Distribution Channel)
- US
- Canada
- Europe (Product Type, Age Group, Application, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Age Group, Application, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Age Group, Application, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Age Group, Application, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Serum Institute of India Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biological E. Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bharat Biotech International Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PT Bio Farma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vaxil Bio Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siam Bioscience Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incepta Vaccine Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- China National Biotec Group Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sinovac Biotech Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MassBiologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Institut Pasteur
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
